Feature | HRS | May 15, 2019| Dave Fornell, Editor

Heart Rhythm Society 2019 Late-Breaking Clinical Trials

HRS late-breaker studies will highlight the biggest news in electrophysiology

HRS 2019 late breaking trials, late breaking presentations for the biggest news in electrophysiology (EP). #HRS #HRS2019 #HRS19

May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm Scientific Sessions. Here is a completed list of the studies presented with links to more information. This includes the latest in clinical research, techniques and technologies in cardiac electrophysiology (EP). For more details on HRS 2019, visit www.hrssessions.org.

 

Late Breaking Clinical Trials Session I
Thursday, May 9, 8 – 9:30 a.m.
   • Transcutaneous Electrical Vagus Nerve Stimulation To Suppress Atrial Fibrillation (TREAT AF): A Randomized Clinical Trial 

   • Prospective Randomized Comparison Of Rotor Ablation vs. Conventional Ablation For Treatment Of Persistent Atrial Fibrillation - The REAFFIRM Trial 

   • Evaluate Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibillation (ERADICATE-AF) Trial  

   • Baroreflex Activation Therapy In Patients With Heart Failure With A Reduced Ejection Fraction  

   • His Corrective Pacing Or Bi-ventricular Pacing For Cardiac Resynchronization In Heart Failure: A Randomized Pilot Trial (HIS SYNC)

 

Late Breaking Clinical Trials Session II: New Data for Device Therapies
Friday, May 10, 1:30 – 3 p.m.
   • Update From The Prevention Of Arrhythmia Device Infection Trial (PADIT); Development Of The PADIT Infection Risk Score 

   • Decline In Ventricular Arrhythmia Events And Mortality In The Multicenter Automatic Defibrillator Implantation Trials  

   • After RAFT: Long Term Outcomes Of Cardiac Resynchronization Therapy  

   • Cardiac Resynchronization Therapy In Chemotherapy-induced Cardiomyopathy: Results Of The Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-induced Cardiomyopathy (MADIT-CHIC) Study

   • Understanding Outcomes With The S-ICD In Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Study: High Conversion Efficacy And Low Adverse Event Rate During The First 30 Days 

 

 
Late Breaking Clinical Trials Session III: Late-Breaking Science
Friday, May 10, 4:30 – 6 p.m.
   • Prospective Evaluation Of Feasibility, Electrophysiological And Echocardiographic Characteristics Of Left Bundle Branch Area Pacing 

   • Is Nonselective His Bundle Pacing Good Enough? Long-term Outcomes From The Geisinger-Rush HBP Registry

   • Preventive Ablation Of Ventricular Tachycardia In Patients With Myocardial Infarction: The BERLIN-VT Trial

   • Five-year Outcomes In Cardiac Surgery Patients With Atrial Fibrillation Undergoing Concomitant Surgical Ablation Versus No Ablation. The Long-term Follow-up of the Prague-12 Study  

   • Real-time Electrogram Analysis For Drivers Of Atrial Fibrillation (Radar): A Multi-center, FDA-IDE, Clinical Trial Of Persistent AF

   • Pulsed Field Ablation For Pulmonary Vein Isolation: Lesion Durability And Chronic Safety  

 

Late Breaking Clinical Trials Session IV: Innovations
Saturday, May 11, 10:30 a.m. - Noon 
   • First-in-human Chronic Implant Experience Of The Medtronic Substernal Extravascular Implantable Cardioverter Defibrillator

   • DIGITAL-AF II: Results From A Real-life Digital Atrial Fibrillation Screening Using Smartphones And Outcome Registry In The General Population

   • Non-invasive Localization Of Cardiac Arrhythmias Using Electromechanical Wave Ultrasound Imaging

   • A Novel Percutaneous Carotid Coil Filter For Stroke Prevention In Atrial Fibrillation: Outcomes Of The First-in-human CAPTURE Trial

   • Bipolar Catheter Ablation For The Treatment Of Refractory Scar-related Ventricular Tachycardia: A Multicenter, Prospective FDA IDE Study

 

 

Other HRS 2019 News:

Survey Shows Big Need for Patient Education on Their Implantable Electrophysiology Devices

Airport Security Body Scanners Do Not Interfere With Pacemakers, ICDs 

Studies Find Race and Gender Disparities in Implantable Heart Devices

HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy

 

New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias

VIDEO: Use of an Antibacterial Envelope to Reduce Infections for Pacemakers, ICDs — Interview with Khaldoun Tarakji, M.D.

VIDEO: Key Trends in Electrophysiology — Apple Watch to Detect AF and the CABANA Trial — Interview with Christine Albert, M.D.,

Find links to other Heart Rhythm Scientific Sessions news

 

 

Industry News at HRS 2019:

Philips and Medtronic Collaborate on Image-guided Atrial Fibrillation Treatment

Abbott Launches Next-generation Confirm RX Implantable Cardiac Monitor

FDA Approves Attain Stability Quad MRI SureScan Lead from Medtronic

Biosense Webster Launches Cartonet Analytics Software for Electrophysiology

 

Murj Launches Murj 2.0 Implantable Cardiac Device Management Software

Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform

CardioFocus Announces European CE Mark Approval Of HeartLight X3 System

Biocardia Receives FDA Clearance for Avance Steerable Introducer Family

 

Spacelabs Debuts Sentinel 11 Cardiology Information Management System

Stereotaxis Announces Next-generation Robotic Magnetic Navigation and Imaging Systems

Preventice Solutions Presents Real-World Performance Data on BodyGuardian Remote Monitoring System With AI

CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study

 

Related Content

Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...